Project Grant K99CA300496
Award Date 8/7/25
Completion Date 7/31/27
Dollars Obligated $134K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $1,396,152 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago. The grant, with a project period from December 5, 2024 to November 30, 2029, aims to examine the role of the BNIP3 gene and mitophagy (the selective degradation of mitochondria) in muscle atrophy during cancer cachexia, which is prevalent in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse...
- This Project Grant award of $432,889 was provided by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The primary objective of this 5-year grant is to apply advanced molecular imaging and metabolotheranostics approaches to better understand and reverse the cachexia (muscle wasting) induced by pancreatic ductal adenocarcinoma (PDAC). The research team at The Johns...
- This federal Project Grant award of $128,199 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the Regents of the University of Michigan to investigate the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC). The research aims to 1) dissect PIKFYVE's function in PDAC metabolism, and 2) determine the mechanism and efficacy of combining PIKFYVE inhibition with KRAS-MAPK inhibition...
- This Project Grant award of $130,501 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) aims to elucidate the role of muscle CDKN1A in cancer cachexia and develop therapeutic strategies targeting the BCL6-CDKN1A pathway. The project will: 1) assess the impact of muscle-specific CDKN1A knockout on muscle function, body composition, metabolism, and survival in cancer cachexia; 2) investigate the temporal regulation of CDKN1A by BCL6 in response to nutrient...
- The Project Grant award of $523,480.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The funding supports research aimed at understanding and overcoming therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC), the third most common cause of cancer-related death in the U.S. Specifically, the project will investigate how disrupting iron metabolism and autophagy pathways...
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- This Project Grant award of $129,624 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the University of Vermont & State Agricultural College (UVM) to investigate the role of adipose tissue (fat) in facilitating tumor growth and cancer cachexia (muscle wasting). The key objectives are to understand how early changes in adipose tissue metabolism can initiate cancer cachexia, and how substrates released from wasting fat and dietary fats impact...
- This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the University of Miami to investigate novel redox stress mechanisms that could inhibit KRAS-driven pancreatic ductal adenocarcinoma (PDAC). The project aims to define the role of the nucleotide pool-cleansing enzyme MTH1 in overcoming tumor-inhibitory reactive oxygen species (ROS) in KRAS-driven PDAC, which accounts for over 90% of PDAC cases. Preliminary data...
- The University of North Carolina at Chapel Hill received a $159,540 Project Grant award from the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports a research project titled "Mechanistic Examination and Inhibitor Targeting of Nutrient Scavenging for the Treatment of Pancreatic Cancer." The project aims to investigate the role of macropinocytosis and autophagy, two metabolic processes that cancer cells use to obtain...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...